How to Get Repatha (Evolocumab) in Illinois

What Is Repatha and Why Does It Require a Prescription?

Repatha is a PCSK9 inhibitor that lowers LDL-cholesterol by blocking the PCSK9 protein, which normally degrades LDL receptors on liver cells. With more receptors available, the liver clears more LDL from circulation. The FDA approved evolocumab in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering beyond maximally tolerated statin therapy. [1]

The FOURIER trial (N=27,564) demonstrated that adding evolocumab to statin therapy reduced the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization by 15% relative to placebo (hazard ratio 0.85; 95% CI 0.79 to 0.92; P<0.001) over a median follow-up of 2.2 years. [2] LDL-C fell by a median of 59% from baseline. Those absolute and relative risk reductions are why guidelines now recommend PCSK9 inhibitors for high-risk patients who do not reach LDL goals on statins alone. [3]

Because evolocumab is a prescription biologic, no Illinois pharmacy can dispense it without a valid prescription from a licensed prescriber. The drug itself is not a controlled substance, but it is subject to standard prescription laws and, almost universally, insurance prior authorization.

Who Can Prescribe Repatha in Illinois?

Any Illinois-licensed prescriber with full prescribing authority can write a Repatha prescription. That includes medical doctors (MD), doctors of osteopathic medicine (DO), nurse practitioners (NP) operating under their full-practice-authority status in Illinois, and physician assistants (PA) with a supervising physician agreement. [4]

Illinois granted NPs full practice authority under the Illinois Nurse Practitioner Full Practice Authority Act, effective January 1, 2024. This means NPs no longer require a collaborative agreement to prescribe, which expands access to PCSK9 inhibitor therapy through primary care and telehealth channels across the state. [4]

Cardiologists and lipidologists write the majority of evolocumab prescriptions, but primary care providers and endocrinologists do so regularly. The ACC/AHA 2018 Guideline on the Management of Blood Cholesterol identifies PCSK9 inhibitors as appropriate add-on therapy when LDL-C remains above 70 mg/dL in very-high-risk ASCVD patients or above 100 mg/dL in high-risk patients despite maximally tolerated statin plus ezetimibe. [3]

Telehealth Access to Repatha in Illinois

Illinois allows telehealth prescribing of non-controlled medications, including biologics like evolocumab, without a mandatory prior in-person visit. The Illinois Telehealth Act (105 ILCS 14) and subsequent amendments permit clinicians to establish a valid patient-provider relationship via synchronous audio-video, making it legal to evaluate, diagnose, and prescribe remotely. [5]

A telehealth encounter for Repatha typically runs 20 to 40 minutes. The clinician reviews your lipid history, statin trial records, any genetic testing for familial hypercholesterolemia, and current medications. If the clinical picture supports a PCSK9 inhibitor, the prescriber sends the prescription electronically to your preferred pharmacy or specialty pharmacy. HealthRX clinicians licensed in Illinois conduct these visits and can initiate the prior authorization process on your behalf.

Recent data from the American Heart Association's 2023 Statistical Update shows that fewer than 5% of ASCVD patients eligible for PCSK9 inhibitors actually receive them, largely due to access and prior-authorization barriers. [6] Telehealth reduces one of those barriers by connecting patients who live in rural Illinois counties, far from academic lipid clinics, with prescribers who specialize in cardiovascular risk reduction.

Labs Required Before Starting Repatha in Illinois

A fasting lipid panel is the minimum lab requirement. Your prescriber will need a documented LDL-C value obtained while you are on maximally tolerated statin therapy to justify the prescription and satisfy prior authorization criteria. Most Illinois Medicaid plans and major commercial insurers (BCBS Illinois, Aetna, Cigna, United Healthcare Illinois) require LDL-C documentation from within the prior 90 days. [7]

Additional labs that insurers commonly request for prior authorization include a complete lipid panel (total cholesterol, HDL-C, non-HDL-C, triglycerides), liver function tests (ALT and AST), a creatine kinase level if myopathy is suspected, and, for patients with suspected familial hypercholesterolemia, documentation of genetic testing or a Dutch Lipid Clinic Network (DLCN) score. [8]

The ACC/AHA 2022 Prevention Guidelines recommend measuring fasting lipids 4 to 12 weeks after initiating or adjusting lipid-lowering therapy, and annually once stable. [9] Those interval measurements also satisfy ongoing prior-authorization renewal requirements for most Illinois plans.

Blood draws can be ordered by your telehealth provider through national reference labs such as LabCorp or Quest Diagnostics, both of which have patient service centers throughout Illinois.

Prior Authorization Requirements in Illinois

Prior authorization (PA) is required by nearly every commercial plan and by Illinois Medicaid for evolocumab. The process is the most common delay in getting Repatha dispensed. Understanding what documentation is needed upfront dramatically shortens the timeline. [7]

Illinois Medicaid (run through managed care organizations including Meridian, Molina, Centene, and CountyCare) covers evolocumab for adults with HeFH, HoFH, or established ASCVD who meet all of the following criteria: [10]

• Documented trial of maximally tolerated statin therapy for at least 90 days
• LDL-C remaining above 70 mg/dL for ASCVD patients, or above 100 mg/dL for FH patients without ASCVD
• Addition of ezetimibe tried or documented as contraindicated
• Diagnosis confirmed by ICD-10 code (E78.01 for HeFH, E78.00 for HoFH, or an established ASCVD code such as I25.10)

Commercial PA packets generally require the same clinical elements plus chart notes documenting the patient's cardiovascular risk category. Amgen's Repatha FIRST program assigns a case manager who can assist with PA submission for commercially insured patients, cutting average PA completion time from 14 days to roughly 7 days when documentation arrives complete. [11]

The HealthRX clinical team uses a PA-readiness checklist before submitting: (1) fasting lipid panel with LDL-C dated within 90 days, (2) statin trial documentation with drug name, dose, and duration, (3) ezetimibe trial or contraindication note, (4) ICD-10 diagnosis code verified against insurer's covered-diagnosis list, and (5) prescriber NPI and DEA numbers on file. Submitting all five elements simultaneously reduces back-and-forth denials by an estimated 40% based on internal HealthRX intake data.

How Long Until You Receive Repatha in Illinois?

The end-to-end timeline from telehealth consult to first injection has three phases. First, the clinical visit itself takes one to two days to schedule and complete. Second, prior authorization review takes 7 to 14 business days, though Illinois law under the Illinois Insurance Code (215 ILCS 5) requires urgent PA decisions within 24 hours and non-urgent decisions within 15 business days. [12] Third, specialty pharmacy processing and shipping adds 2 to 5 business days.

Patients who already have recent labs and statin documentation can often receive their first Repatha SureClick autoinjector within 14 to 21 calendar days of their telehealth visit. Patients starting from scratch who need new labs drawn should plan for 4 to 6 weeks total.

Amgen's free 30-day trial offer (available at the time of publication for commercially insured patients) can allow you to receive your first supply while the PA is still pending, avoiding a gap in therapy. [11]

How to Transfer a Repatha Prescription to Illinois

If you have an existing evolocumab prescription from another state and have moved to Illinois, the prescription can generally be transferred to an Illinois-licensed pharmacy provided the original prescription was written by a licensed prescriber and has refills remaining. Illinois pharmacy law (225 ILCS 85) allows transfers between licensed pharmacies in different states for non-controlled medications. [13]

The receiving pharmacy must verify the original prescription with the dispensing pharmacy and confirm the prescribing clinician's license is valid. If the out-of-state prescriber is not licensed in Illinois, you will need a new prescription from an Illinois-licensed provider. A telehealth visit is the fastest way to establish care with a new Illinois prescriber without driving to a clinic.

Specialty pharmacies that operate nationally, including CVS Specialty, Walgreens Specialty, and Accredo, maintain pharmacy licenses in Illinois and can receive transferred prescriptions or accept new prescriptions from Illinois telehealth providers without requiring you to visit a physical location. [13]

503A Compounding Pharmacies and Evolocumab in Illinois

A PCSK9 inhibitor such as evolocumab is a biologic monoclonal antibody. Biologics present particular challenges for compounding because reproducing a 140-mg monoclonal antibody with verified potency, purity, and sterility outside a licensed biopharmaceutical manufacturing facility is technically demanding. The FDA has not placed evolocumab on any 503A or 503B compounding-permitted list as of the date of this article. [14]

Illinois-licensed 503A compounding pharmacies can legally compound medications for individual patients when a commercially available product is not available or appropriate, but compounding a monoclonal antibody like evolocumab is not standard practice in Illinois 503A pharmacies due to these manufacturing constraints. [14] If you encounter a pharmacy advertising compounded evolocumab, request documentation of the pharmacist's compounding authority and confirm with the Illinois Department of Professional Regulation that the pharmacy holds an active compounding license.

For patients who need a PCSK9 inhibitor but face Repatha access barriers, the FDA-approved alternative inclisiran (Leqvio, Novartis) is administered by a clinician twice yearly and may have different formulary positioning on some Illinois plans. [15] Alirocumab (Praluent, Sanofi/Regeneron) is the other FDA-approved PCSK9 inhibitor and may carry a lower co-pay tier on certain Illinois formularies. [16]

Cost and Patient Assistance for Repatha in Illinois

Repatha's list price is approximately $5,800 to $6,400 per year before discounts as of early 2025. Few commercially insured patients pay list price. Amgen's copay card program reduces out-of-pocket cost to as low as $5 per month for eligible commercially insured patients. Patients without insurance or with Medicare Part D can apply to Amgen's patient assistance program (Amgen Safety Net Foundation), which provides Repatha at no cost to qualifying patients below 400% of the federal poverty level. [11]

The ODYSSEY OUTCOMES trial for alirocumab and the FOURIER trial for evolocumab both demonstrated cost-effectiveness below $100,000 per quality-adjusted life year in very-high-risk ASCVD subgroups, which has informed some insurer formulary decisions favoring broader access. [2] [17]

Illinois Medicaid beneficiaries enrolled in the fee-for-service program or a managed care plan pay standard Medicaid co-pays (typically $4 for generic, but biologics like Repatha may have a higher tier co-pay depending on the MCO contract). Contact your Illinois Medicaid managed care plan directly to verify your tier placement before filling.

Starting Evolocumab: Dose, Administration, and Monitoring

The standard FDA-approved dosing for HeFH and established ASCVD is evolocumab 140 mg subcutaneous injection every 2 weeks, or 420 mg once monthly using three consecutive 140 mg injections within 30 minutes. [1] For HoFH, the monthly 420 mg dose is standard.

Repatha is supplied as a prefilled SureClick autoinjector or a SureClick single-use prefilled syringe. It is stored in the refrigerator (36 to 46°F) and can be kept at room temperature (up to 77°F) for up to 30 days. Injection sites include the abdomen, upper arm, or thigh. Rotate sites with each injection.

Monitoring after starting therapy follows ACC/AHA guidance: measure fasting lipids 4 to 12 weeks after initiation to confirm response, then every 3 to 12 months. [9] A 50% or greater LDL-C reduction from baseline is the expected response in most patients. In FOURIER, evolocumab achieved a mean LDL-C of 30 mg/dL (from a baseline of 92 mg/dL) in the active treatment group. [2]

Common adverse effects include injection-site reactions in approximately 3% of patients, nasopharyngitis, and upper respiratory tract infection at rates similar to placebo. [1] Serious hypersensitivity reactions are rare. No routine safety labs beyond lipids are required during ongoing therapy, though liver function tests at baseline are standard practice. [8]

The ACC/AHA 2022 Prevention Guidelines state: "For patients with clinical ASCVD at very high risk, if LDL-C remains greater than or equal to 70 mg/dL on maximally tolerated statin plus ezetimibe therapy, adding a PCSK9 inhibitor is recommended (Class I, Level of Evidence: A)." [9]

Step-by-Step: Getting Repatha Through HealthRX in Illinois

1. Schedule a telehealth visit with a HealthRX clinician licensed in Illinois. The visit is conducted by synchronous video and takes approximately 30 minutes.
2. Before your visit, gather your most recent fasting lipid panel, a list of statin medications you have tried (drug name, dose, and duration), and your insurance card.
3. During the visit, the clinician confirms your diagnosis, reviews your cardiovascular risk category per ACC/AHA 2018 Guideline criteria, and determines whether evolocumab meets your clinical needs. [3]
4. If appropriate, the clinician sends the prescription electronically to your preferred specialty pharmacy and submits the prior authorization request with your complete documentation.
5. The HealthRX care coordination team tracks your PA status and contacts you when approved.
6. Your specialty pharmacy ships Repatha directly to your Illinois home address.
7. A follow-up telehealth visit is scheduled 4 to 6 weeks after your first injection to review a repeat lipid panel and confirm response.

Patients who arrive at step one with all documentation in hand typically receive their first injection within 14 to 21 days. Patients who need labs drawn first should expect 4 to 6 weeks.